Refusal to License Patents

Yes — the right to refuse to license is a fundamental attribute of patent ownership in the United States: THE CORE RIGHT TO EXCLUDE: 35 U.S.C. § 154(a)(1) grants the patent owner the right to exclude others from making, using, offering for sale, or selling the patented invention; the right to EXCLUDE includes the right to refuse to license — a patent owner cannot be required to affirmatively share the invention with anyone; HISTORICAL FOUNDATION: Continental Paper Bag Co. v. Eastern Paper Bag Co. (S.Ct. 1908): the Supreme Court held that a patent owner could enforce its patent even if it had never used the patent and had no intention of using it; the right to exclude encompasses the right to refuse to deal; the fact that a refusal eliminates competition in a market does not make the refusal unlawful; STATUTORY RECOGNITION OF THE RIGHT: 35 U.S.C. § 271(d)(4): it is not patent misuse for a patent holder to refuse to license or use any rights to the patent — Congress explicitly confirmed the right to refuse to license as NOT constituting patent misuse; WHY THE RIGHT TO REFUSE IS IMPORTANT: it allows patent holders to maintain exclusivity as a competitive advantage; it allows patent holders to demand higher royalties rather than being forced to license at any price; it preserves the patent holder's choice of business model (vertical integration vs. licensing); UNILATERAL REFUSAL VS. CONDITIONAL REFUSAL: UNILATERAL REFUSAL: simply refusing to license at any price; generally lawful; CONDITIONAL REFUSAL: refusing to license unless the licensee also licenses back competing patents, or refuses to license to certain competitors, or attaches other conditions; conditional refusals can raise antitrust concerns (tying; exclusive dealing); THE POLICY TRADEOFF: the right to refuse to license creates a tension with antitrust goals; courts have consistently resolved this tension in favor of the patent right, finding that a unilateral refusal to license is not normally an antitrust violation, because the patent system itself created the right to exclude.

While refusal to license is generally lawful, a small number of antitrust theories can create liability in extreme circumstances: THE GENERAL RULE — REFUSAL TO LICENSE IS LAWFUL: courts have consistently held that unilateral refusal to license a patent is NOT an antitrust violation even if the refuser has monopoly power and the refusal harms competition; VERIZON COMMUNICATIONS v. LAW OFFICES OF CURTIS TRINKO (S.Ct. 2004): the Supreme Court reinforced that there is no general duty to deal with competitors; unilateral refusal to deal is only an antitrust violation in extreme circumstances where: (1) the refusal terminates a prior course of dealing, AND (2) there is no legitimate business justification for the termination; ASPEN SKIING CO. v. ASPEN HIGHLANDS SKIING CORP. (S.Ct. 1985): found antitrust liability for refusal to deal where the defendant had previously shared joint tickets with the plaintiff and then abruptly terminated the arrangement to harm a competitor — the refusal was irrational except for its exclusionary purpose; ESSENTIAL FACILITIES DOCTRINE: the controversial theory that a monopolist who controls an essential facility (one a competitor cannot practically duplicate) must provide access; courts have been skeptical of this doctrine in patent cases; Trinko rejected it; CONDITIONAL REFUSAL RAISING ANTITRUST CONCERNS: refusing to license UNLESS the competitor pays supracompetitive royalties (above FRAND rates for standard-essential patents) can raise antitrust concerns; refusing to license UNLESS the competitor agrees not to challenge the patent's validity; refusing to license to certain types of customers or restricting licensee's market (vertical restrictions); PRICE SQUEEZE: a vertically integrated company that refuses to license its patents at reasonable royalties, while competing against unlicensed downstream competitors, can raise a price squeeze theory in some jurisdictions; LEVERAGE OF STANDARD-ESSENTIAL PATENTS: the most important exception to the general rule — if a patent owner committed to FRAND licensing during standard adoption, then refuses to license on FRAND terms, this is: a breach of the FRAND contract; potentially a violation of § 2 of the Sherman Act (attempted monopolization through breach of FRAND commitment); a basis for injunctive relief in patent cases to be denied (eBay four-factor test); INTERNATIONAL DISTINCTION: the EU and some other jurisdictions are more willing to find antitrust liability for refusal to license by dominant companies; EU competition law recognizes an essential facilities doctrine more broadly than US law; US companies that refuse to license SEPs in EU markets should evaluate EU competition law exposure separately.

Standard-essential patents (SEPs) are the most significant exception to the general right to refuse to license: WHAT ARE SEPs: a standard-essential patent covers technology that is essential to implement an industry standard (Wi-Fi, LTE, 5G, USB, HDMI, Bluetooth, H.264/HEVC video codecs, etc.); a patent is essential if it is impossible to implement the standard without practicing the patent; STANDARD-SETTING ORGANIZATIONS (SSOs): industry standards are developed by SSOs like IEEE, ETSI, 3GPP, JEDEC, and others; SSOs typically require members to disclose patents they believe are essential to the standard being developed; and to commit to licensing those patents on FRAND terms (fair, reasonable, and non-discriminatory) to all who need to implement the standard; WHY FRAND MATTERS: if a patent holder could refuse to license or demand exorbitant royalties for SEPs after a standard is adopted, it could hold up the entire industry; once an industry adopts a standard and invests in building products for that standard, they have no practical alternative — creating lock-in that the SEP holder can exploit; the FRAND commitment is the price of having the patent included in the standard; BREACH OF FRAND OBLIGATIONS: if a SEP holder committed to FRAND licensing and then: refuses to license at all; demands unreasonably high royalties (royalty stacking); refuses to license to downstream implementers (only licensing to manufacturers but not component suppliers); this constitutes breach of the FRAND contract; the aggrieved party (the implementer) can: sue for breach of contract; seek specific performance of the FRAND commitment; assert antitrust violations for refusal to deal in violation of FRAND; INJUNCTIONS AND SEPS: eBay v. MercExchange (S.Ct. 2006) eliminated the automatic grant of permanent injunctions in patent cases and required application of the four-factor test; courts have consistently found that SEP holders who have committed to FRAND licensing cannot easily obtain permanent injunctions because: they have indicated willingness to license (undercuts irreparable harm showing); monetary damages (FRAND royalty) are an adequate remedy; the public interest generally disfavors injunctions on standardized technology; ITC AND SEPs: the ITC has a separate analysis for SEPs and generally declines to grant exclusion orders for SEPs where FRAND commitments exist; CALCULATION OF FRAND ROYALTIES: the subject of enormous litigation; courts use methodologies like: comparable license analysis; top-down analysis (total industry revenue × reasonable royalty rate ÷ number of SEPs); smallest salable patent-practicing unit (SSPPU) analysis to avoid royalty stacking.

Compulsory licensing is a mechanism that allows a government or authorized party to use a patent without the patent holder's consent: THE GENERAL RULE IN THE US — NO GENERAL COMPULSORY PATENT LICENSING: unlike many other countries, the United States does NOT have a general compulsory patent licensing regime; a US patent owner cannot typically be forced to license its patent to a competitor under normal commercial circumstances; SPECIFIC US STATUTORY COMPULSORY LICENSES: despite the general rule, several specific US statutes create limited compulsory licensing: (1) GOVERNMENT USE (28 U.S.C. § 1498): the US government may use any patented invention without the patent owner's consent; the government's contractor may also use the patent on behalf of the government; the patent owner is entitled to reasonable compensation; this is the most commonly invoked US compulsory license; pharmaceutical companies have feared this provision might be invoked during public health crises; (2) BAYH-DOLE MARCH-IN RIGHTS: for inventions developed with federal funding, 35 U.S.C. § 203 allows the government to grant compulsory licenses if the patent holder: fails to achieve practical application of the invention; fails to satisfy health or safety needs; fails to meet requirements for public use specified by federal regulations; march-in rights have been petitioned many times (often for high-drug prices) but NEVER invoked by the NIH or any other agency as of 2025; (3) CLEAN AIR ACT § 308: the EPA administrator can require compulsory licensing of a patent if it is necessary to enable compliance with Clean Air Act requirements; (4) ATOMIC ENERGY ACT: compulsory licensing for nuclear technology; INTERNATIONAL COMPULSORY LICENSING — TRIPS AGREEMENT: TRIPS Agreement Article 31 (and the 2001 Doha Declaration) allows member states to grant compulsory licenses for: national emergencies and other circumstances of extreme urgency; public non-commercial use; anti-competitive practices (to remedy); WTO members have used compulsory licensing for AIDS drugs and other medications; the US has generally opposed compulsory licensing of pharmaceutical patents internationally; PRACTICAL SIGNIFICANCE: for US patent strategy, compulsory licensing risks are low except: for government procurement contracts where § 1498 applies; for federally funded research subject to Bayh-Dole; for standard-essential patents where FRAND commitments substitute for compulsory licensing in some respects.